CARVYKTI 3.2 × 106-1.0 × 108 celule dispersie perfuzabila cells dispersion for infusion JANSSEN
Chemical substance: ciltacabtagen autoleucel
ATC code: L0XX • Antineoplastic and immunomodulating agents |
Active substance
Results for the substance ciltacabtagen autoleucel
1 result
About this active substance
Ciltacabtagene autoleucel is a CAR-T cell therapy used for the treatment of relapsed or refractory multiple myeloma. It involves the genetic modification of the patient's T cells to recognize and destroy tumor cells expressing the BCMA antigen.
The treatment is administered via intravenous infusion after a process of T cell collection and modification. It is important for patients to be closely monitored to prevent severe adverse reactions, such as cytokine release syndrome.
Patients should be aware of potential side effects, such as fever, fatigue, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as cytokine release syndrome or neurotoxicity may occur. Patients should be informed of these risks before starting treatment.
The treatment is administered via intravenous infusion after a process of T cell collection and modification. It is important for patients to be closely monitored to prevent severe adverse reactions, such as cytokine release syndrome.
Patients should be aware of potential side effects, such as fever, fatigue, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as cytokine release syndrome or neurotoxicity may occur. Patients should be informed of these risks before starting treatment.